Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Zarate

Showing results (41-50 of 707) with videos related to

Pageof 71
Sort By:
Bipolar Disorders|December 1, 2016
GSK-3: A key regulatory target for ketamine's rapid antidepressant effects mediated by enhanced AMPA to NMDA throughputCarlos A Zarate, Rodrigo Machado-Vieira
Bipolar Disorders|May 6, 2018
Preventing suicide: A multicausal model requires multimodal research and interventionElizabeth D Ballard, Carlos A Zarate
The Journal of Clinical Psychiatry|June 14, 2013
Current status of ketamine and related compounds for depressionDaniel C Mathews, Carlos A Zarate
The New England Journal of Medicine|February 7, 2019
Depression in the Primary Care SettingLawrence T Park, Carlos A Zarate
American Journal of Medical Genetics. Part A|October 25, 2016
SATB2-associated syndrome: Mechanisms, phenotype, and practical recommendationsYuri A Zarate, Jennifer L Fish
Journal of Neurosurgery|February 1, 1992
Reconstruction of the temporalis muscleR Castillo, A Zarate, R Chavez
Lancet (London, England)|October 23, 2008
Fabry's diseaseYuri A Zarate, Robert J Hopkin
CNS Drugs|June 26, 2009
Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorderCarlos A Zarate, Husseini K Manji
Current Psychiatry Reports|August 17, 2013
Ketamine, sleep, and depression: current status and new questionsWallace C Duncan, Carlos A Zarate
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 18, 2020
Biologically plausible models of neural dynamics for rapid-acting antidepressant interventionsJessica R Gilbert, Carlos A Zarate
Pageof 71

Showing results (41-50 of 707) with videos related to

Sort By:
Pageof 71
Bipolar Disorders|December 1, 2016
GSK-3: A key regulatory target for ketamine's rapid antidepressant effects mediated by enhanced AMPA to NMDA throughputCarlos A Zarate, Rodrigo Machado-Vieira
Bipolar Disorders|May 6, 2018
Preventing suicide: A multicausal model requires multimodal research and interventionElizabeth D Ballard, Carlos A Zarate
The Journal of Clinical Psychiatry|June 14, 2013
Current status of ketamine and related compounds for depressionDaniel C Mathews, Carlos A Zarate
The New England Journal of Medicine|February 7, 2019
Depression in the Primary Care SettingLawrence T Park, Carlos A Zarate
American Journal of Medical Genetics. Part A|October 25, 2016
SATB2-associated syndrome: Mechanisms, phenotype, and practical recommendationsYuri A Zarate, Jennifer L Fish
Journal of Neurosurgery|February 1, 1992
Reconstruction of the temporalis muscleR Castillo, A Zarate, R Chavez
Lancet (London, England)|October 23, 2008
Fabry's diseaseYuri A Zarate, Robert J Hopkin
CNS Drugs|June 26, 2009
Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorderCarlos A Zarate, Husseini K Manji
Current Psychiatry Reports|August 17, 2013
Ketamine, sleep, and depression: current status and new questionsWallace C Duncan, Carlos A Zarate
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 18, 2020
Biologically plausible models of neural dynamics for rapid-acting antidepressant interventionsJessica R Gilbert, Carlos A Zarate
Pageof 71